Publications by authors named "Charles Ludgate"

Claim this Profile
T
Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy.
Lisa Ds Johnson, Nancy J Nesslinger, Paul A Blood, Navraj Chima, Lindsay R Richier, Charles Ludgate

Oncoimmunology· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing cancer treatments to induce an acute immune response: radiation Abscopal effects, PAMPs, and DAMPs.
Charles M Ludgate

Clin Cancer Res· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
Abraham S Alexander, Aminudin Mydin, Stuart O Jones, Jennifer Christie, Jan T W Lim, Charles M Ludgate

Int J Radiat Oncol Biol Phys· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective evaluation of a 12-week walking exercise program and its effect on fatigue in prostate cancer patients undergoing radical external beam radiotherapy.
Pauline T Truong, Catherine A Gaul, Rachel E McDonald, Ross B Petersen, Stuart O Jones, Charles Ludgate

Am J Clin Oncol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.
Abraham Alexander, Juanita Crook, Stuart Jones, Shawn Malone, Julie Bowen, Charles Ludgate

Int J Radiat Oncol Biol Phys· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model.
Sara Hahn, Nancy J Nesslinger, Robert J Drapala, Mary Bowden, Paul S Rennie, Charles Ludgate

Int J Cancer· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
Howard Huaihan Pai, Brenna Eldridge, Darcy Bishop, Abraham Alexander, Mary Lesperance, Charles Ludgate

Can J Urol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer.
Juanita Crook, Charles Ludgate, Shawn Malone, Gad Perry, Libni Eapen

Int J Radiat Oncol Biol Phys· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial.
Juanita M Crook, Shawn Malone, Gad Perry, Libni Eapen, Julie Owen, Charles Ludgate

Cancer· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.
Anthony V D'Amico, James W Denham, Juanita Crook, Ming-Hui Chen, Samuel Z Goldhaber, Charles Ludgate

J Clin Oncol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard treatments induce antigen-specific immune responses in prostate cancer.
Nancy J Nesslinger, Robert A Sahota, Brad Stone, Kayli Johnson, Navraj Chima, Charles Ludgate

Clin Cancer Res· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapy.
Howard Huaihan Pai, Charles Ludgate, Tom Pickles, Chuck Paltiel, Alex Agranovich

Int J Radiat Oncol Biol Phys· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters.
Nicholas Bruchovsky, Laurence Klotz, Juanita Crook, Shawn Malone, Charles Ludgate

Cancer· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy.
Pauline T Truong, Eric Berthelet, Junella C Lee, Ross Petersen, Jan T W Lim, Charles M Ludgate

Can J Urol· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.
Charles M Ludgate, Darcy C Bishop, Howard Pai, Brenna Eldridge, Jan Lim

Int J Radiat Oncol Biol Phys· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Juanita Crook, Charles Ludgate, Shawn Malone, Jan Lim, Gad Perry

Int J Radiat Oncol Biol Phys· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis